A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma

William Bensinger, Richard T. Maziarz, Sundar Jagannath, Andrew Spencer, Simon Durrant, Pamela S. Becker, Brett Ewald, Sanela Bilic, John Rediske, Johan Baeck, Edward A. Stadtmauer

Research output: Contribution to journalArticlepeer-review

97 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences